Integrated Biopharma, Inc.
INBP
$0.32
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.72% | 8.02% | 4.67% | 3.18% | -0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.72% | 8.02% | 4.67% | 3.18% | -0.47% |
| Cost of Revenue | 3.47% | 5.08% | 1.21% | -0.25% | -1.62% |
| Gross Profit | 17.79% | 43.20% | 49.94% | 51.64% | 13.53% |
| SG&A Expenses | -3.06% | -2.50% | -3.12% | -2.79% | -6.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.00% | 4.53% | 0.90% | -0.44% | -1.95% |
| Operating Income | 112.96% | 704.78% | 2,645.83% | 478.33% | 2,108.33% |
| Income Before Tax | 114.43% | 669.40% | 3,085.71% | 494.31% | 2,052.63% |
| Income Tax Expenses | 178.87% | 703.85% | 1,083.02% | 3,193.75% | 304.17% |
| Earnings from Continuing Operations | 56.28% | 621.43% | 1,181.03% | 341.04% | 841.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.28% | 621.43% | 1,181.03% | 341.04% | 841.38% |
| EBIT | 112.96% | 704.78% | 2,645.83% | 478.33% | 2,108.33% |
| EBITDA | 80.18% | 318.46% | 781.97% | 3,150.00% | 195.21% |
| EPS Basic | 55.24% | 624.32% | 1,164.10% | 338.76% | 815.00% |
| Normalized Basic EPS | 109.94% | 658.93% | 3,084.62% | 505.26% | 2,037.50% |
| EPS Diluted | 52.45% | 616.22% | 1,156.41% | 337.98% | 815.00% |
| Normalized Diluted EPS | 113.94% | 701.92% | 2,620.00% | 490.91% | 2,257.14% |
| Average Basic Shares Outstanding | 1.45% | 0.77% | 0.47% | 0.42% | 0.49% |
| Average Diluted Shares Outstanding | 2.17% | 2.11% | 1.63% | 0.41% | -0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |